Literature DB >> 11350402

Does age influence the behaviour of localized prostate cancer?

C C Parker1, M Gospodarowicz, P Warde.   

Abstract

OBJECTIVE: To assess, in a meta-analysis of published studies, whether age influences the behaviour of localized prostate cancer.
METHODS: The Medline database was searched from 1966 to 2000 to identify studies analysing the outcome of localized prostate cancer by age, using disease-specific outcome measures, and having controlled for the established prognostic factors of grade, T stage and, where available, serum prostate-specific antigen (PSA) level.
RESULTS: In all, 34 studies were identified, which included a total of 27 551 patients. The incomplete and heterogeneous nature of the reports precluded any quantitative overview. The findings of these reports are described and methodological shortcomings discussed.
CONCLUSION: The evidence suggests that young age was an adverse prognostic factor in some series of radiation therapy before the advent of PSA assays, when men typically presented clinically with locally advanced disease, but that age has no significant prognostic effect in contemporary series of localized prostate cancer. Possible explanations for this difference are discussed, together with implications for further studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350402     DOI: 10.1046/j.1464-410x.2001.02141.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  9 in total

1.  Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy.

Authors:  Sıtkı Ün; Hakan Türk; Osman Koca; Rauf Taner Divrik; Ferruh Zorlu
Journal:  Turk J Urol       Date:  2015-06

2.  A 43-year-old African American man with low-risk prostate cancer.

Authors:  Mark Soloway
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

Review 3.  Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials.

Authors:  Daniel A Hamstra; Kyounghwa Bae; Miljenko V Pilepich; Gerald E Hanks; David J Grignon; David G McGowan; Mack Roach; Colleen Lawton; R Jeffrey Lee; Howard Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-31       Impact factor: 7.038

4.  Is Age an Independent Factor for Prostate Cancer? A Paired Analysis.

Authors:  José Arnaldo Shiomi da Cruz; Carlo C Passerotti; Sabrina Thalita Dos Reis; Mary Ellen Salles Guariero; Olimpio Daniel de Campos; Katia Ramos Moreira Leite; Miguel Srougi
Journal:  Curr Urol       Date:  2016-12-26

5.  Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future.

Authors:  R D Riley; K R Abrams; A J Sutton; P C Lambert; D R Jones; D Heney; S A Burchill
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

6.  Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts.

Authors:  Cécile Proust-Lima; Jeremy M G Taylor; Scott G Williams; Donna P Ankerst; Ning Liu; Larry L Kestin; Kyounghwa Bae; Howard M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-01       Impact factor: 7.038

7.  High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.

Authors:  S G Zhao; W C Jackson; V Kothari; M J Schipper; N Erho; J R Evans; C Speers; D A Hamstra; Y S Niknafs; P L Nguyen; E M Schaeffer; A E Ross; R B Den; E A Klein; R B Jenkins; E Davicioni; F Y Feng
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-05-19       Impact factor: 5.554

8.  Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC).

Authors:  Michael R Humphreys; Kimberly A Fernandes; Srikala S Sridhar
Journal:  J Cancer       Date:  2013-03-21       Impact factor: 4.207

Review 9.  Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond.

Authors:  R D Riley; W Sauerbrei; D G Altman
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.